Intralesional Kenalog Injections for Recurrent Cutaneous Rosai-Dorfman Disease (RDD) in the Lower Extremity

Main Article Content

Victoria Jiminez
Lawangeen Zeb
Lauren Graham
Anna Gray


Rosai Dorfman disease, Cutaneous Rosai-Dorfman Disease, Recurerrence, extremities, Treatment, Excision, Intralesional Kenalog


Rosai-Dorfman disease (RDD) is a rare disorder of histiocytic origin with nodal, extranodal, and cutaneous classifications often presenting as eruptive rashes, most commonly affecting the face, trunk, and thigh. Due to its rarity, no consensus exists regarding standard of care for these lesions, as most knowledge regarding treatment is provided by case reports. To our knowledge, we report the first case of a patient with a recurrent lower extremity mass consistent with cutaneous RDD, despite surgical excision and topical steroids treatment. A 51-year-old female presented with recurrent RDD after failed treatment with clobetasol ointment and surgical excision at an outside practice. Examination revealed violaceous plaques with overlying scale, without lymphadenopathy. With the failure of the previous excision, the patient was prescribed 5 mg/ml intralesional Kenalog (ILK) injections to suppress inflammation of the lesion. She experienced improved clinical response to treatment and remission of active disease with residual post-inflammatory hyperpigmentation at 10 months after two rounds of injections, although the patient reported vast improvement at 5 months as well. Treatment of RDD is difficult due to its rarity, hindering clinical trial development. Therapeutics reported to be efficacious include topical, intralesional, and systemic steroids, retinoids, methotrexate, chemotherapy, cryotherapy, phototherapy, and radiation. Clinical management is variable and often requires multiple forms of treatment on a case-to-case basis, highlighting the need for larger clinical studies to establish a standard of care. Our case poses interest in the use of ILK for RDD and should be considered in recurrent cases after prior surgical excision.


1. Al-Khateeb TH. Cutaneous Rosai-Dorfman Disease of the Face: A Comprehensive Literature Review and Case Report. J Oral Maxillofac Surg. 2016;74(3):528-540. doi:10.1016/j.joms.2015.09.017

2. Karami R, Ghieh F, Baroud J, Abu Sittah G. Rosai-Dorfman Disease: Cutaneous and Parotid Involvement. Ann Plast Surg. 2019;82(6):639-641. doi:10.1097/SAP.0000000000001794

3. Ahmed A, Crowson N, Magro CM. A comprehensive assessment of cutaneous Rosai-Dorfman disease. Ann Diagn Pathol. 2019;40:166-173. doi:10.1016/j.anndiagpath.2019.02.004

4. Gawdzik A, Ziarkiewicz-Wróblewska B, Chlebicka I, Jankowska-Konsur A, Szepietowski JC, Maj J. Cutaneous Rosai-Dorfman Disease: A Treatment Challenge. Dermatol Ther (Heidelb). 2021;11(4):1443-1448. doi:10.1007/s13555-021-00557-1

5. Subash JJ, Kesty C, Kesty KR, Asgari M, Jorizzo J. Low-dose weekly methotrexate used to treat cutaneous Rosai-Dorfman disease. Clin Exp Dermatol. 2018;43(7):849-851. doi:10.1111/ced.13665

6. Gameiro A, Gouveia M, Cardoso JC, Tellechea O. Histological variability and the importance of clinicopathological correlation in cutaneous Rosai-Dorfman disease. An Bras Dermatol. 2016;91(5):634-637. doi:10.1590/abd1806-4841.20164477

7. Sun L, Shi J, Su Z, Zhang M, Lu Y. Successful treatment of Rosai-Dorfman disease using ALA-PDT. Photodiagnosis Photodyn Ther. 2018;21:128-129. doi:10.1016/j.pdpdt.2017.11.014

8. Park AY, Lee HJ, Hong SA, Kim JE. Successful Treatment of Cutaneous Rosai-Dorfman Disease With Pulsed Dye Laser. Dermatol Surg. 2020;46(2):286-289. doi:10.1097/DSS.0000000000001798

9. Fening K, Bechtel M, Peters S, Zirwas M, Darabi K. Cutaneous rosai-dorfman disease persisting after surgical excision: report of a case treated with acitretin. J Clin Aesthet Dermatol. 2010;3(9):34-36.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)